Danaher, a life sciences company, announced plans to launch its first AI-powered autonomous research lab early next year, aiming to enhance the speed and efficiency of drug discovery and development. Here are the key highlights:
- The lab will combine AI, robotics, and technologies from various Danaher subsidiaries, aiming for scalability by early 2027.
- It is designed to accelerate molecule discovery by eight times and significantly increase the annual generation of target-binding molecules by tenfold.
- JC Gutierrez-Ramos, Danaher’s chief science officer, stated that this innovation will allow scientists to concentrate on complex challenges requiring human insight.
- The lab employs AI to synthesize new molecules that bind to specific biological targets, such as antibodies, and iteratively improves designs based on testing results.
- This initiative is part of a larger program at Danaher to develop a range of smart instruments.
Reported by Sneha S K in Bengaluru
